Market Overview

CytRx Closes Offering of 9.2M Shares

Related CYTR
Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage
Benzinga's Top Upgrades, Downgrades For May 3, 2018

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, announced today the closing of its previously announced underwritten public offering of 9,200,000 shares of common stock, including the exercise of the over-allotment option by the underwriters covering 1,200,000 shares, at a public offering price of $2.50 per share. The gross proceeds to CytRx from the offering, including the exercise of the over-allotment option, were $23 million, before deducting underwriting discounts and commissions and other offering expenses payable by CytRx.

Posted-In: News Offerings


Related Articles (CYTR)

View Comments and Join the Discussion!

3D Systems Partners With Singularity University

UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Harley-Davidson